her3-dxd

Advanced Solid Tumor

Daiichi SankyoPhase 2Active

CC

46/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 59/ 100

Competitive context

1411 Active assets in the Advanced Solid Tumor cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

her3-dxd is also rated in:

non-small cell lung carcinomaDormant

B

Indicative ·

59 / 100

ovarian carcinomaDormant

CCC

Indicative ·

53 / 100

exocrine pancreatic carcinomaDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.